Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00930982 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT00930982 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 124 participants.
The verdict
NCT00930982, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if bacterial load in the airways can be reduced after inhalation of ciprofloxacin for 28 days.
Interventions
- DRUG Placebo
- DRUG Ciprofloxacin (Cipro, BAYQ3939)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00930982
The ClinicalTrials.gov registry entry for NCT00930982 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00930982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00930982 about?
NCT00930982 is a clinical study titled "Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis". The purpose of this study is to find out if bacterial load in the airways can be reduced after inhalation of ciprofloxacin for 28 days.
What is the current status of trial NCT00930982?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2009-06. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00930982?
The interventions under investigation include: Placebo (DRUG), Ciprofloxacin (Cipro, BAYQ3939) (DRUG).
Who is sponsoring clinical trial NCT00930982?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.